Literature DB >> 12969246

Inclusion formation in Huntington's disease R6/2 mouse muscle cultures.

M Orth1, J M Cooper, G P Bates, A H V Schapira.   

Abstract

Huntington's disease (HD) is an autosomal dominant disorder caused by an expansion in the number of glutamine repeats in the N-terminal region of the huntingtin protein. Nuclear and cytoplasmic aggregates of the N-terminal portion of huntingtin have been found in the brains of HD patients and the brains and non-neuronal tissues of the R6/2 HD transgenic mouse. We have cultured myoblasts and myotubes from transgenic R6/2 mice and littermate controls to investigate the formation of these inclusions in post mitotic cells. Huntingtin immunoreactivity was intense in differentiating, desmin positive myoblasts and myotubes from both control and R6/2 mice suggesting that it may play a role in myotube differentiation. Following differentiation huntingtin and ubiquitin positive aggregates were observed in R6/2 but not control cultures. After 3 weeks in differentiation medium cytoplasmic huntingtin and ubiquitin immunoreactive aggregates were observed in non-myotube cells, while nuclear huntingtin aggregates were seen in a proportion of myotubes after 6 weeks. Growth in the absence of serum resulted in a marked increase in the number of R6/2 myotubes containing nuclear inclusions after 6 weeks demonstrating that environmental factors influenced huntingtin aggregate formation in these cells. Consequently, cultured myotubes from R6/2 mice may be a useful post mitotic cell culture model to study both the biochemical consequences of huntingtin aggregates and the factors that may influence aggregate formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12969246     DOI: 10.1046/j.1471-4159.2003.02009.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  19 in total

1.  Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease.

Authors:  Kuan-Yu Liu; Yu-Chiau Shyu; Brett A Barbaro; Yuan-Ta Lin; Yijuang Chern; Leslie Michels Thompson; Che-Kun James Shen; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2014-11-14       Impact factor: 6.150

2.  Measures of growth in children at risk for Huntington disease.

Authors:  Jessica K Lee; Kathy Mathews; Bradley Schlaggar; Joel Perlmutter; Jane S Paulsen; Eric Epping; Leon Burmeister; Peg Nopoulos
Journal:  Neurology       Date:  2012-07-18       Impact factor: 9.910

3.  The Expanding Clinical Universe of Polyglutamine Disease.

Authors:  Shanshan Huang; Suiqiang Zhu; Xiao-Jiang Li; Shihua Li
Journal:  Neuroscientist       Date:  2019-01-07       Impact factor: 7.519

4.  Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington's disease.

Authors:  Pengxiang She; Zhiyou Zhang; Deanna Marchionini; William C Diaz; Thomas J Jetton; Scot R Kimball; Thomas C Vary; Charles H Lang; Christopher J Lynch
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-04-19       Impact factor: 4.310

5.  Cardiac dysfunction in the R6/2 mouse model of Huntington's disease.

Authors:  Michael J Mihm; Deborah M Amann; Brandon L Schanbacher; Ruth A Altschuld; John Anthony Bauer; Kari R Hoyt
Journal:  Neurobiol Dis       Date:  2006-11-27       Impact factor: 5.996

6.  Impaired PGC-1alpha function in muscle in Huntington's disease.

Authors:  Rajnish K Chaturvedi; Peter Adhihetty; Shubha Shukla; Thomas Hennessy; Noel Calingasan; Lichuan Yang; Anatoly Starkov; Mahmoud Kiaei; Milena Cannella; Jenny Sassone; Andrea Ciammola; Fernando Squitieri; M Flint Beal
Journal:  Hum Mol Genet       Date:  2009-05-21       Impact factor: 6.150

7.  CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse.

Authors:  I Dragatsis; D Goldowitz; N Del Mar; Y P Deng; C A Meade; Li Liu; Z Sun; P Dietrich; J Yue; A Reiner
Journal:  Neurobiol Dis       Date:  2008-11-06       Impact factor: 5.996

Review 8.  An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity.

Authors:  G Cisbani; F Cicchetti
Journal:  Cell Death Dis       Date:  2012-08-30       Impact factor: 8.469

Review 9.  Besides Huntington's disease, does brain-type creatine kinase play a role in other forms of hearing impairment resulting from a common pathological cause?

Authors:  Yow-Sien Lin; Chin-Hung Wang; Yijuang Chern
Journal:  Aging (Albany NY)       Date:  2011-06       Impact factor: 5.682

Review 10.  Purine Nucleotides Metabolism and Signaling in Huntington's Disease: Search for a Target for Novel Therapies.

Authors:  Marta Tomczyk; Talita Glaser; Ewa M Slominska; Henning Ulrich; Ryszard T Smolenski
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.